(Q46897347)

26 December 2017

title

PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan (English)

1 reference

26 December 2017

1 reference

1 reference

1 reference

E Goshen

1

1 reference

26 December 2017

T Davidson

series ordinal

2

1 reference

26 December 2017

S T Zwas

series ordinal

3

1 reference

26 December 2017

D Aderka

series ordinal

4

1 reference

26 December 2017

publication date

1 February 2006

1 reference

26 December 2017

Technology in Cancer Research and Treatment

published in

1 reference

26 December 2017

volume

5

1 reference

26 December 2017

page(s)

37-43

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

cites work

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

Maximizing the potential of bevacizumab in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

What can we learn from phase II adjuvant trials in melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

Molecular imaging of antiangiogenic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153303460600500105

10.1177/153303460600500105

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

16417400

1 reference

26 December 2017